Bio-Techne Corp (TECH) Stock Price, Quote & News

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth f...

Industry: Biotechnology

Sector: Healthcare

Phone: 612 379 8854

Fax: 612 656 4400

Website: www.bio-techne.com

Address:

614 McKinley Place N.E., Minneapolis, United States

Estimize Sep. 4 at 11:03 AM

Wall St is expecting 0.43 EPS for $TECH Q1 [Reporting 11/04 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

0 · Reply

RunnerSignals Sep. 3 at 9:08 PM

Stock Upgrades Today 1/2 $AIRS $HUBS $TECH $TECK $TRU catching attention today with upgrades fueling momentum and renewed investor interest https://stocksrunner.com/news/2025-09-03-stock-upgrades-today-signal-big-moves-traders-should-watch

0 · Reply

JarvisFlow Sep. 3 at 1:57 PM

RBC Capital has adjusted their stance on Bio-Techne ( $TECH ), setting the rating to Outperform with a target price of 61 → 73.

0 · Reply

SSRKitty Sep. 3 at 1:36 PM

$GNS I need an app developer anyone that's an app developer HMU $NVDA $GRRR $TECH

1 · Reply

Stockprofiler Sep. 3 at 12:54 PM

$RGBP $RGBPP Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market; FDA clearance received for Phase 1 clinical trial of HemaXellerate with Potential market opportunity exceeding $1 billion annually in chemotherapy-induced bone marrow suppression-Partnership with experienced CRO for trial execution and Possibility for accelerated regulatory pathways and market exclusivity due to orphan indication status https://stocktitan.net/news/RGBP/regen-bio-pharma-discusses-potential-impact-of-hema-xellerate-on-9podp4spyr4n.html AMGN AZN BMRN BNTX $GILD MRNA ONC SNY $TECH VRTX #FDA #TECH

2 · Reply

d_risk Aug. 22 at 4:20 PM

$TECH - Bio-Techne Corp Common Stock - 10K - Updated Risk Factors TECH’s 2025 10-K risk factors spotlight heightened exposure to global economic slowdowns, supply chain and workforce disruptions, geopolitical conflicts, regulatory and compliance costs, R&D funding volatility, and data security threats, while removing climate, competition, and product liability risks, and adding new concerns on acquisitions, IP, and dividend reductions. #Biotechnology #DividendReduction #IntellectualProperty #AcquisitionRisk #DataSecurity #R&DFundingVolatility #RegulatoryCompliance #GeopoliticalRisk #WorkforceChallenges #SupplyChainDisruption #GlobalEconomicSlowdown 🟢 Added 🟠 Removed https://d-risk.ai/TECH/10-K/2025-08-22

0 · Reply

JarvisFlow Aug. 21 at 1:00 PM

Citigroup has adjusted their stance on Bio-Techne ( $TECH ), setting the rating to Buy with a target price of 55 → 70.

0 · Reply

StockAutoPro Aug. 18 at 7:26 AM

$TECH: Buy target $51.6 Sell target $56.28 Strong quarterly earnings report could indicate potential growth for this leading cloud computing company.

0 · Reply

JarvisFlow Aug. 7 at 2:45 PM

RBC Capital has updated their rating for Bio-Techne ( $TECH ) to Sector Perform with a price target of 61.

0 · Reply

ZacksResearch Aug. 6 at 2:26 PM

$TECH beats earnings estimates, but the stock dips — what's going on? 🤔 Adjusted EPS of 53 cents beat the Zacks Consensus Estimate by 6%, with revenue up 3.5% year over year. Yet, shares dropped 1.2% pre-market as gross margins contracted and operating income turned negative. 📉 Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2672794/bio-techne-q4-earnings-beat-estimates-gross-margin-down-stock-falls?cid=sm-stocktwits-2-2672794-body-6294&ADID=SYND_STOCKTWITS_TWEET_2_2672794_BODY_6294

0 · Reply

Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 9, 2025, 7:00 AM EDT - 15 hours ago

ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California

Sep 3, 2025, 3:42 PM EDT - 6 days ago

Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 7:00 AM EDT - 13 days ago

Bio-Techne to Present at Upcoming Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 26 days ago

ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory

Aug 6, 2025, 12:52 PM EDT - 4 weeks ago

Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript

Aug 6, 2025, 8:08 AM EDT - 4 weeks ago

Bio-Techne beats quarterly estimates on strength in protein sciences unit

Aug 6, 2025, 6:30 AM EDT - 4 weeks ago

BIO-TECHNE DECLARES DIVIDEND

Aug 6, 2025, 6:30 AM EDT - 4 weeks ago

Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

Aug 5, 2025, 4:30 PM EDT - 5 weeks ago

Bio-Techne Announces Exosome Diagnostics Divestiture

Aug 5, 2025, 7:00 AM EDT - 5 weeks ago

ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine

Jul 31, 2025, 9:52 AM EDT - 5 weeks ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG LLY PODD

Jul 31, 2025, 7:00 AM EDT - 5 weeks ago

ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering

Jul 28, 2025, 1:19 PM EDT - 6 weeks ago

Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell

Jul 17, 2025, 7:00 AM EDT - 7 weeks ago

Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results

Jul 15, 2025, 9:03 AM EDT - 2 months ago

Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology

Jul 15, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

Jul 14, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

ABEO

Jun 24, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

Jun 10, 2025, 7:00 AM EDT - 3 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

May 29, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne to Present at Investor Conferences

May 14, 2025, 7:00 AM EDT - 4 months ago

ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)

May 12, 2025, 7:00 AM EDT - 4 months ago

Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

May 8, 2025, 9:30 AM EDT - 4 months ago

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing

May 8, 2025, 7:00 AM EDT - 4 months ago

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

May 7, 2025, 10:38 AM EDT - 4 months ago

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript

May 7, 2025, 8:18 AM EDT - 4 months ago

Bio-Techne exceeds profit expectations, announces new share buyback plan

May 7, 2025, 6:30 AM EDT - 4 months ago

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

May 7, 2025, 6:30 AM EDT - 4 months ago

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

May 6, 2025, 7:00 AM EDT - 4 months ago

ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.

Apr 29, 2025, 7:00 AM EDT - 4 months ago

ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy

Apr 24, 2025, 7:00 AM EDT - 4 months ago

Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection

Apr 23, 2025, 7:00 AM EDT - 4 months ago

Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 2, 2025, 7:00 AM EDT - 5 months ago

Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument

Mar 26, 2025, 7:00 AM EDT - 5 months ago

Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany

Mar 24, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting

Mar 10, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System

Mar 3, 2025, 7:00 AM EST - 6 months ago

Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes

Feb 27, 2025, 9:00 AM EST - 6 months ago

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Feb 20, 2025, 7:00 AM EST - 7 months ago

Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology

Feb 18, 2025, 7:00 AM EST - 7 months ago

Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System

Feb 5, 2025, 2:24 PM EST - 7 months ago

Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript

Feb 5, 2025, 6:30 AM EST - 7 months ago

Bio-Techne Declares Dividend

Feb 5, 2025, 6:30 AM EST - 7 months ago

Bio-Techne Releases Second Quarter Fiscal 2025 Results

Feb 4, 2025, 7:00 AM EST - 7 months ago

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

Jan 21, 2025, 7:00 AM EST - 8 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio

Jan 21, 2025, 7:00 AM EST - 8 months ago

Bio-Techne to Host Conference Call on February 5, 2025, to Announce Second Quarter Fiscal 2025 Financial Results

Jan 10, 2025, 7:00 AM EST - 8 months ago

Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine

Jan 8, 2025, 7:00 AM EST - 8 months ago

BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025

Jan 8, 2025, 7:00 AM EST - 8 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics

Estimize Sep. 4 at 11:03 AM

Wall St is expecting 0.43 EPS for $TECH Q1 [Reporting 11/04 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

0 · Reply

RunnerSignals Sep. 3 at 9:08 PM

0 · Reply

JarvisFlow Sep. 3 at 1:57 PM

RBC Capital has adjusted their stance on Bio-Techne ( $TECH ), setting the rating to Outperform with a target price of 61 → 73.

0 · Reply

SSRKitty Sep. 3 at 1:36 PM

$GNS I need an app developer anyone that's an app developer HMU $NVDA $GRRR $TECH

1 · Reply

Stockprofiler Sep. 3 at 12:54 PM

2 · Reply

d_risk Aug. 22 at 4:20 PM

0 · Reply

JarvisFlow Aug. 21 at 1:00 PM

Citigroup has adjusted their stance on Bio-Techne ( $TECH ), setting the rating to Buy with a target price of 55 → 70.

0 · Reply

StockAutoPro Aug. 18 at 7:26 AM

$TECH: Buy target $51.6 Sell target $56.28 Strong quarterly earnings report could indicate potential growth for this leading cloud computing company.

0 · Reply

JarvisFlow Aug. 7 at 2:45 PM

RBC Capital has updated their rating for Bio-Techne ( $TECH ) to Sector Perform with a price target of 61.

0 · Reply

ZacksResearch Aug. 6 at 2:26 PM

0 · Reply

CrispDry Aug. 6 at 1:43 PM

$TECH complete dogsh*t $PRGO

0 · Reply

ZacksResearch Aug. 6 at 12:07 PM

$TECH beats on Q4 earnings — so why is the stock dropping? The company topped estimates, but gross margin declined and shares sold off on the report. Full breakdown of what moved the stock 👉 https://www.zacks.com/stock/news/2672794/bio-techne-q4-earnings-beat-estimates-gross-margin-down-stock-falls?cid=sm-stocktwits-2-2672794-teaser-6210&ADID=SYND_STOCKTWITS_TWEET_2_2672794_TEASER_6210

0 · Reply

Estimize Aug. 6 at 10:00 AM

Wall St is expecting 0.44 EPS for $TECH Q1 [Reporting 11/04 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

0 · Reply

OptionRunners Aug. 5 at 6:44 PM

$TECH Buyer of the August 15th $50 calls (ITM) 400 times for $5.90 ahead of earnings tomorrow morning. Repeat flow

0 · Reply

ZacksResearch Aug. 4 at 2:32 PM

$TECH Q4 earnings: Can Bio-Techne defy the odds? 🤔 🌐 Revenue estimate up 3.7% YoY to $317.4M 🔍 Spatial Biology segment set for modest growth ⚠️ Zacks Rank #4 (Sell) + Earnings ESP of 0.00% = cautious outlook In-depth analysis here 👉 https://www.zacks.com/stock/news/2662135/bio-techne-q4-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2662135-body-5663&ADID=SYND_STOCKTWITS_TWEET_2_2662135_BODY_5663

0 · Reply

ZacksResearch Aug. 4 at 1:27 PM

Q4 setup for $TECH — bullish or bust? Investors are eyeing Bio-Techne’s upcoming Q4 report to gauge revenue trends and margin stability in a tough biotech tape. Full earnings preview here 👉 https://www.zacks.com/stock/news/2662135/bio-techne-q4-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2662135-teaser-5630&ADID=SYND_STOCKTWITS_TWEET_2_2662135_TEASER_5630

0 · Reply

OptionRunners Jul. 31 at 2:43 PM

$TECH Buyer of the August 15th $55 calls (ITM) 1,000 times for $5.00 ahead of earnings on 8/6

0 · Reply

lanky9622 Jul. 29 at 9:24 PM

$XDC.X Just got the inside scoop on a hot new quantum startup, PsiPi.Ai. They’re bringing novel quantum-field modulation tech that could challenge the dominant players. Keep an eye on this one! 🔥 $IONQ $RGTI $IBM #Quantum #Startups #DeepTech $TECH

1 · Reply

shitzushimazu Jul. 28 at 2:20 AM

$TECH turn up time?

0 · Reply

jtrader8000 Jul. 25 at 5:46 AM

$TECH TECH - great ticker, good bounce off lows which isnt far away so very easy to manage downside from here, has been on big runs before 2022 highs, so hopefully this is the start of another run

0 · Reply

Fizz26 Jul. 24 at 11:16 PM

$DJIA $TECH great balance sheet and undervalued

0 · Reply

JarvisFlow Jul. 11 at 3:15 PM

Scotiabank updates rating for Bio-Techne ( $TECH ) to Sector Outperform, target set at 90 → 75.

0 · Reply

Market Cap	8.48B
Revenue (ttm)	1.22B
Net Income (ttm)	73.40M
EPS (ttm)	N/A
PE Ratio	31.45
Forward PE	30.87
Profit Margin	6.02%
Debt to Equity Ratio	0.18

Volume	2,229,700
Avg Vol	2,120,578
Day's Range	N/A - N/A
Shares Out	156.77M
Stochastic %K	45%
Beta	1.47
Analysts	Strong Sell
Price Target	$66.50